APA (7th ed.) Citation

Kutsch, N., Giza, A., Robrecht, S., Stumpf, J., Federhen, A., Stoltefuß, A., . . . Schlenska‐Lange, A. (2024). Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry. European Journal of Haematology, 113(2), 235. https://doi.org/10.1111/ejh.14220

Chicago Style (17th ed.) Citation

Kutsch, Nadine, et al. "Fludarabine, Cyclophosphamide, and Rituximab as First‐line Treatment in Patients with Chronic Lymphocytic Leukemia: A Long‐term Analysis of the German CLL Study Group (GCLLSG) Registry." European Journal of Haematology 113, no. 2 (2024): 235. https://doi.org/10.1111/ejh.14220.

MLA (9th ed.) Citation

Kutsch, Nadine, et al. "Fludarabine, Cyclophosphamide, and Rituximab as First‐line Treatment in Patients with Chronic Lymphocytic Leukemia: A Long‐term Analysis of the German CLL Study Group (GCLLSG) Registry." European Journal of Haematology, vol. 113, no. 2, 2024, p. 235, https://doi.org/10.1111/ejh.14220.